Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2021

Open Access 01-12-2021 | Osteosarcoma | Research

A genome-wide expression profile of noncoding RNAs in human osteosarcoma cells as they acquire resistance to cisplatin

Authors: Harshita Sharma, Divya Niveditha, Rajdeep Chowdhury, Sudeshna Mukherjee, Shibasish Chowdhury

Published in: Discover Oncology | Issue 1/2021

Login to get access

Abstract

Background

Recurrence after cisplatin therapy is one of the major hindrances in the management of cancer. This necessitates a deeper understanding of the molecular signatures marking the acquisition of resistance. We therefore modeled the response of osteosarcoma (OS) cells to the first-line chemotherapeutic drug cisplatin. A small population of nondividing cells survived acute cisplatin shock (persisters; OS-P). These cells regained proliferative potential over time re-instating the population again (extended persisters; OS-EP).

Result

In this study, we present the expression profile of noncoding RNAs in untreated OS cells (chemo-naive), OS-P, OS-EP and drug-resistant (OS-R) cells derived from the latter. RNA sequencing was carried out, and thereafter, differential expression (log2-fold ± 1.5; p value ≤ 0.05) of microRNAs (miRNAs) was analyzed in each set. The core set of miRNAs that were uniquely or differentially expressed in each group was identified. Interestingly, we observed that most of each group had their own distinctive set of miRNAs. The miRNAs showing an inverse correlation in expression pattern with mRNAs were further selected, and the key pathways regulated by them were delineated for each group. We observed that pathways such as TNF signaling, autophagy and mitophagy were implicated in multiple groups.

Conclusion

To the best of our knowledge, this is the first study that provides critical information on the variation in the expression pattern of ncRNAs in osteosarcoma cells and the pathways that they might tightly regulate as cells acquire resistance.
Appendix
Available only for authorised users
Literature
1.
Bielack S, Jürgens H, Jundt G, Kevric M, Kühne T, Reichardt P, et al. Osteosarcoma: the COSS experience. In: Cancer Treatment and Research. 2009.
2.
Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. 2018.
3.
Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer. 2001;37(1):32–8.PubMedCrossRef
4.
Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415–20.PubMedCrossRef
5.
Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6(7):1075–85.PubMedCrossRef
6.
Blay JY. Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. Onkologie. 2007;30(5):226–7.PubMed
7.
Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007;19(4):341–6.PubMedCrossRef
8.
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom Proteom Bioinform. 2016;14:42–54.CrossRef
9.
Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet. 2019;11(1):1–24.CrossRef
10.
Yang T, Shi Y, Yildirim E. Implications of long noncoding RNAs in cancer epigenetics. In: Chakrabarti J, Mitra S, editors. Translational epigenetics, cancer and noncoding RNAs. Academic Press; 2018. pp. 381–406. 
11.
Rna N, Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62.CrossRef
12.
Sinha S, Boila LD, Chatterjee SS, Sengupta A. miRNA and cancer: a deadly liaison? In: Chakrabarti J, Mitra S, editors. Translational epigenetics, cancer and noncoding RNAs. Academic Press; 2018. pp. 27–46.
13.
Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75:467–84.PubMedCrossRef
14.
15.
16.
Chen R, Wang G, Zheng Y, Hua Y, Cai Z. Drug resistance-related microRNAs in osteosarcoma: translating basic evidence into therapeutic strategies. J Cell Mol Med. 2019;23(4):2280–92.PubMedPubMedCentralCrossRef
17.
Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu J, et al. Potential regulatory role of lncRNA–miRNA–mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.PubMedCrossRef
18.
Mukherjee S, Dash S, Lohitesh K, Chowdhury R. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. PLoS ONE. 2017;12(6):e0179203.PubMedPubMedCentralCrossRef
19.
Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K. Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 2009;14(1):108–23.PubMedCrossRef
20.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–8.PubMedCrossRef
21.
Ray U, Roy SS, Chowdhury SR. Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1. Cell Physiol Biochem. 2017;41:795–805.PubMedCrossRef
22.
Niveditha D, Mukherjee S, Majumder S, Chowdhury R, Chowdhury S. A global transcriptomic pipeline decoding core network of genes involved in stages leading to acquisition of drug-resistance to cisplatin in osteosarcoma cells. Bioinformatics. 2019;35:1701–11.PubMedCrossRef
23.
Hao S, Tian W, Chen Y, Wang L, Jiang Y, Gao B, et al. MicroRNA-374c-5p inhibits the development of breast cancer through TATA-box binding protein associated factor 7-mediated transcriptional regulation of DEP domain containing 1. J Cell Biochem. 2019;120:15360–8.PubMedPubMedCentralCrossRef
24.
Wilczyński M, Żytko E, Szymańska B, Dzieniecka M, Nowak M, Danielska J, et al. Expression of miR-146a in patients with ovarian cancer and its clinical significance. Oncol Lett. 2017;14:3207–14.PubMedPubMedCentralCrossRef
25.
Chijiiwa Y, Moriyama T, Ohuchida K, Nabae T, Ohtsuka T, Miyasaka Y, et al. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Int J Oncol. 2016;48:1688–700.PubMedCrossRef
26.
Luo YJ, Huang QM, Ren Y, Liu ZL, Xu CF, Wang H, et al. Non-coding RNA in drug resistance of gastric cancer. World J Gastrointest Oncol. 2019;11:957–70.PubMedPubMedCentralCrossRef
27.
Lin SL, Lin YH, Chi HC, Lin TK, Chen WJ, Yeh CT, et al. A novel long non-coding RNA-01488 suppressed metastasis and tumorigenesis by inducing miRNAs that reduce vimentin expression and ubiquitination of cyclin E. Cells. 2020;9(6):1504.PubMedCentralCrossRef
28.
Li S, Wu D, Jia H, Zhang Z. Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC. Cell Death Dis. 2020;11(8):1–12.PubMedPubMedCentralCrossRef
29.
Li Z, Feng C, Guo J, Hu X, Xie D. GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization. Funct Integr Genom. 2020;20:17–28.CrossRef
30.
Zheng JZ, Huang YN, Yao L, Liu YR, Liu S, Hu X, et al. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. Sci Rep. 2018;8:1–11.
31.
32.
Gu C, Cai J, Xu Z, Zhou S, Ye L, Yan Q, et al. MiR-532-3p suppresses colorectal cancer progression by disrupting the ETS1/TGM2 axis-mediated Wnt/β-catenin signaling. Cell Death Dis. 2019;10(10):1–14.CrossRef
33.
Guo X, Chen Z, Zhao L, Cheng D, Song W, Zhang X. Long non-coding RNA-HAGLR suppressed tumor growth of lung adenocarcinoma through epigenetically silencing E2F1. Exp Cell Res. 2019;382:111461.PubMedCrossRef
34.
Xiong G, Huang H, Feng M, Yang G, Zheng S, You L, et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2018;37:1–15.CrossRef
35.
Geng J, Liu Y, Jin Y, Tai J, Zhang J, Xiao X, et al. MicroRNA-365a-3p promotes tumor growth and metastasis in laryngeal squamous cell carcinoma. Oncol Rep. 2016;35:2017–26.PubMedCrossRef
36.
Wang X, Liu Z, Tong H, Peng H, Xian Z, Li L, et al. Linc01194 acts as an oncogene in colorectal carcinoma and is associated with poor survival outcome. Cancer Manag Res. 2019;11:2349–62.PubMedPubMedCentralCrossRef
37.
Zhong Y, Lu Q, Qiu W, Luo Y. LINC00636 promotes lymph node metastasis and cervical cancer through targeting NM23. Biosci Rep. 2020;40:1–10.CrossRef
38.
Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, et al. MIR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 2018;9(5):1–17.CrossRef
39.
Zhang J, Cao Z, Yang G, You L, Zhang T, Zhao Y. MicroRNA-27a (miR-27a) in solid tumors: a review based on mechanisms and clinical observations. Front Oncol. 2019;9:893.PubMedPubMedCentralCrossRef
40.
Su C, Huang DP, Liu JW, Liu WY, Cao YO. miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1. Oncol Lett. 2019;18:2825–34.PubMedPubMedCentral
41.
Yan X, Yu H, Liu Y, Hou J, Yang Q, Zhao Y. miR-27a-3p functions as a tumor suppressor and regulates non-small cell lung cancer cell proliferation via targeting HOXB8. Technol Cancer Res Treat. 2019;18:1–7.CrossRef
42.
Swayden M, Chhouri H, Anouar Y, Grumolato L. Tolerant/persister cancer cells and the path to resistance to targeted therapy. Cells. 2020;9:1–13.CrossRef
43.
De Conti G, Dias MH, Bernards R. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers. 2021;13:1–15.CrossRef
44.
45.
Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, et al. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy. Oncol Rep. 2014;31:613–8.PubMedCrossRef
46.
Aakko S, Straume AH, Birkeland EE, Chen P, Qiao X, ’Lønning PE, et al. MYC-induced miR-203b-3p and miR-203a-3p control Bcl-xL expression and paclitaxel sensitivity in tumor cells. Transl Oncol. 2019;12:170–9.PubMedCrossRef
47.
Ma R, Zhao Y, He M, Zhao H, Zhang Y, Zhou S, et al. Identifying a ten-microRNA signature as a superior prognosis biomarker in colon adenocarcinoma. Cancer Cell Int. 2019;19:1–16.CrossRef
48.
Zhao J, Tao Y, Zhou Y, Qin N, Chen C, Tian D, et al. MicroRNA-7: a promising new target in cancer therapy. Cancer Cell Int. 2015;15:1–8.CrossRef
49.
Wang K, Yang S, Gao Y, Zhang C, Sui Q. MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/ß-catenin signaling pathway. Oncol Lett. 2020;19:992–1000.PubMed
50.
Wang Y, Zhang S, Bao H, Mu S, Zhang B, Ma H, et al. MicroRNA-365 promotes lung carcinogenesis by downregulating the USP33/SLIT2/ROBO1 signalling pathway. Cancer Cell Int. 2018;18:1–14.CrossRef
51.
Hong S, Li S, Bi M, Yu H, Yan Z, Liu T, et al. Long non-coding RNA ILF3-AS1 promotes proliferation and metastasis of colorectal cancer cells by recruiting histone methylase EZH2 to induce H3K27me3 and downregulate CDKN2A. Mol Ther Nucleic Acids. 2021;24:1012–23.PubMedPubMedCentralCrossRef
52.
Cheng C, Wang Q, Zhu M, Liu K, Zhang Z. Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients. Cancer Cell Int. 2019;19:1–17.CrossRef
53.
Qian C, Xu Z, Chen L, Wang Y, Yao J. Long noncoding RNA LINC01391 restrained gastric cancer aerobic glycolysis and tumorigenesis via targeting miR-12116/CMTM2 axis. J Cancer. 2020;11:6264–76.PubMedPubMedCentralCrossRef
54.
Li N, Yang L, Wang H, Yi T, Jia X, Chen C, et al. MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS ONE. 2015;10:1–12.
55.
Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, et al. Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells. Surg Today. 2020;50:1099–106.PubMedCrossRef
56.
Uhr K, Prager-Van der Smissen WJC, Heine AAJ, Ozturk B, van Jaarsveld MTM, Boersma AWM, et al. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS ONE. 2019;14:1–18.CrossRef
57.
Xing C, Sun SG, Yue ZQ, Bai F. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother. 2021;134:111158.PubMedCrossRef
58.
Shen Q, Xu Z, Xu S. Long non-coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR-514a-3p/ULK1 axis in human non-small cell lung cancer. Int J Oncol. 2020;57:967–79.PubMedPubMedCentral
59.
Wu R, Li L, Bai Y, Yu B, Xie C, Wu H, et al. The long noncoding RNA LUCAT1 promotes colorectal cancer cell proliferation by antagonizing nucleolin to regulate MYC expression. Cell Death Dis. 2020;11:1–13.CrossRef
60.
Nweke EE, Brand M. Downregulation of the let-7 family of microRNAs may promote insulin receptor/insulin-like growth factor signalling pathways in pancreatic ductal adenocarcinoma. Oncol Lett. 2020;20:2613–20.PubMedPubMedCentralCrossRef
61.
Ganesan S, Palani HK, Lakshmanan V, Balasundaram N, Alex AA, David S, et al. Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death Dis. 2019;10(10):1–14.CrossRef
62.
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li DM, et al. Downregulation of miR-218 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. Oncogene. 2017;36:2577–88.PubMedPubMedCentralCrossRef
63.
Yan S, Wang H, Chen X, Liang C, Shang W, Wang L, et al. MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C. Cancer Lett. 2020;488:18–26.PubMedCrossRef
64.
65.
66.
Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018;8:1–25.CrossRef
Metadata
Title
A genome-wide expression profile of noncoding RNAs in human osteosarcoma cells as they acquire resistance to cisplatin
Authors
Harshita Sharma
Divya Niveditha
Rajdeep Chowdhury
Sudeshna Mukherjee
Shibasish Chowdhury
Publication date
01-12-2021
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-021-00441-6

Other articles of this Issue 1/2021

Discover Oncology 1/2021 Go to the issue

Research

RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma

Research

Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis

Research

FAM65A as a novel prognostic biomarker in human tumors reveal by a pan-cancer analysis

Research

Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression

Clinical Trial

Sphincter preservation in patients with low rectal cancer: striking the right oncological balance

Review

Cancer chemoprevention through Frizzled receptors and EMT
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits